Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Minerva Surgical to $1 from $5 and keeps an Overweight rating on the shares following the Q1 sales beat. With the company having addressed its near-term financing issue, continued sales momentum "should help reinvigorate sentiment on the name," the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on UTRS:
- Minerva Surgical Reports First Quarter 2023 Financial Results
- UTRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Minerva Surgical to Announce First Quarter 2023 Financial Results
- Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer
- Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results